State Street Corp Has $4.87 Million Stock Position in Omeros Co. (NASDAQ:OMER)

State Street Corp raised its holdings in Omeros Co. (NASDAQ:OMER) by 0.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,226,053 shares of the biopharmaceutical company’s stock after acquiring an additional 3,839 shares during the quarter. State Street Corp owned about 2.12% of Omeros worth $4,867,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. HighTower Advisors LLC boosted its position in Omeros by 7.2% during the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 4,000 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Omeros by 6.1% during the 2nd quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock valued at $454,000 after acquiring an additional 6,435 shares during the period. BNP Paribas Financial Markets lifted its position in Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Omeros by 4.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock worth $1,926,000 after purchasing an additional 18,454 shares during the last quarter. Finally, SPC Financial Inc. acquired a new stake in shares of Omeros in the 3rd quarter valued at approximately $77,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on OMER. RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. D. Boral Capital assumed coverage on Omeros in a research report on Monday, December 23rd. They issued a “buy” rating and a $36.00 target price for the company. Rodman & Renshaw assumed coverage on shares of Omeros in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price target on the stock. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Thursday, December 19th. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Omeros Stock Up 11.7 %

NASDAQ OMER opened at $11.68 on Monday. The stock’s 50 day moving average is $7.73 and its 200 day moving average is $5.43. The firm has a market capitalization of $676.86 million, a PE ratio of -5.06 and a beta of 1.97. Omeros Co. has a twelve month low of $2.61 and a twelve month high of $13.60.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.